Routes of Drug Administration

Last updated 1 Jun 2026 · Palliative care

📋 Key Information Summary

📋

The chosen drug route should be effective and least burdensome for the patient; always start with the least invasive option compatible with clinical goals.
Oral administration remains the preferred route in palliative care until swallowing difficulties, nausea/vomiting, poor absorption, or inadequate symptom control necessitate a change.
Sublingual and buccal routes bypass first-pass hepatic metabolism and are useful when oral swallowing is impaired but the patient retains mucosal integrity.
Enteral tubes (nasogastric, PEG/PEJ) allow continued enteral drug delivery; however, not all oral formulations are suitable for crushed or liquid administration through tubes.
Transdermal patches provide steady-state drug delivery over 24–72 hours, are ideal for patients unable to swallow, and avoid repeated needle-sticks — but onset is slow (12–24 h for fentanyl patches).
Transdermal patches must not be cut (unless specifically designed for it), must be applied to intact, non-irradiated skin, and are affected by fever and high ambient temperatures.
The subcutaneous (SC) route is the workhorse parenteral route in Australian palliative care; butterfly needles and syringe drivers (e.g., Graseby™, McKinley™) enable continuous SC infusions.
SC infusions allow reliable delivery of multiple medications simultaneously (e.g., morphine + midazolam + hyoscine butylbromide) and are preferred over IV in community palliative settings.
When switching routes, use published equianalgesic conversion ratios and reduce the calculated dose by 25–50% to account for incomplete cross-tolerance.
Regular medication review is essential in palliative care — medications should be rationalised as the patient's condition changes; polypharmacy is a significant source of burden.
Special considerations apply in renal impairment (avoid morphine metabolites; prefer fentanyl or hydromorphone), hepatic impairment (reduce doses, avoid hepatotoxic agents), and paediatric palliative care (weight-based dosing, limited transdermal options).
Aboriginal and Torres Strait Islander patients in remote communities may face barriers including limited pharmacy access, language differences, and cultural considerations around end-of-life medications; involve Indigenous health workers early.

Introduction & Australian Context

Selecting the appropriate route of drug administration is a fundamental clinical decision in palliative care. The overarching principle is to choose the route that is effective, least burdensome, and aligned with the patient's goals of care. As disease progresses, the ability to take medications orally may be lost, necessitating timely transition to alternative routes to maintain symptom control and comfort.

In Australia, palliative care is delivered across diverse settings — inpatient palliative care units, general hospital wards, residential aged care facilities, and the community (including remote and very remote areas). The Australian Institute of Health and Welfare (AIHW) reports that approximately 70% of Australians express a preference to die at home, yet the majority of deaths still occur in hospital. Reliable drug delivery across all settings is essential to support place-of-care preferences.

This topic covers the principal routes of drug administration used in Australian palliative medicine:

Oral route — including sublingual and buccal absorption
Enteral tube route — nasogastric (NG), percutaneous endoscopic gastrostomy (PEG), and percutaneous endoscopic jejunostomy (PEJ)
Transdermal route — medicated patches and topical preparations
Subcutaneous route — intermittent injection and continuous infusion via syringe drivers

Other routes (rectal, intranasal, intrathecal, epidural) are used in select circumstances but are beyond the scope of this article. Intravenous administration is uncommon in community palliative care in Australia and is generally reserved for acute hospital settings.

💡

Core principle: Anticipate the need for route changes. Discuss alternative routes with the patient and family early, before an acute change in clinical status forces an emergency transition. This anticipatory approach is a hallmark of quality palliative care and is emphasised by Palliative Care Australia's National Palliative Care Standards (2018).

Oral Route

The oral route is the default and preferred route of drug administration in palliative care. It is non-invasive, familiar to patients, self-administered (promoting autonomy), and has the broadest range of available formulations. Oral administration should be maintained for as long as the patient can safely and effectively swallow and absorb medications.

When Oral Is Appropriate

Patient can swallow tablets, capsules, or liquids safely
No significant nausea or vomiting that would impair absorption
Functional gastrointestinal tract with adequate absorption
Sufficient time to onset (not needed urgently — otherwise consider SC)
Patient preference supports oral administration

Oral Formulation Options

Formulation	Advantages	Disadvantages	Palliative Examples
Tablets (standard)	Stable, accurate dosing, wide availability	May be difficult to swallow; some cannot be crushed	Morphine SR tablets, paracetamol, dexamethasone
Orodispersible / Wafer	Dissolves on tongue; no water needed	Limited range; may be unpalatable	Ondansetron ODT (Ondemet®), lorazepam sublingual
Liquids / Solutions	Flexible dosing, easy to swallow, can be given via syringe	Taste, bulk, some require refrigeration	Morphine IR solution (Ordine®), dexamethasone elixir
Sublingual tablets	Rapid onset, bypasses first-pass metabolism	Limited drug range; requires mucosal integrity	Fentanyl SL (Abstral®), buprenorphine SL (Temgesic®)
Buccal films	Applied to inner cheek; steady absorption	Unfamiliar technique; mucosal irritation	Fentanyl buccal (Onsolis® — not PBS-listed)
Capsules (can sprinkle)	Contents can often be sprinkled on soft food	Not all capsules can be opened; taste	Dexamethasone capsules (opened), some antiemetics

Sublingual and Buccal Absorption

The sublingual mucosa is highly vascularised, allowing rapid drug absorption directly into the systemic circulation via the sublingual veins, bypassing the portal system and first-pass hepatic metabolism. This is particularly valuable for:

Breakthrough cancer pain: Fentanyl sublingual tablets (Abstral®) or intranasal fentanyl provide rapid onset (5–15 minutes) for episodic pain
Nausea when swallowing is impaired: Ondansetron orodispersible wafers dissolve on the tongue
Anxiety and agitation: Lorazepam (Ativan®) can be administered sublingually; onset within 15–20 minutes
End-of-life symptom management: Sublingual midazolam for terminal restlessness when SC access is not available or not desired

⚠️

Dry mouth caution: Many palliative care patients have xerostomia (dry mouth) from dehydration, anticholinergic medications, or radiotherapy. Sublingual and buccal absorption requires adequate mucosal moisture. Address dry mouth with regular mouth care, saliva substitutes, or consider switching to SC if absorption is unreliable.

When to Transition Away from Oral

Indications to change from the oral route include:

Dysphagia (oropharyngeal or oesophageal) — assessed clinically or by speech pathology
Persistent nausea and vomiting not controlled by antiemetics
Mucositis (grade 3–4) preventing comfortable oral intake
Reduced consciousness or coma
Bowel obstruction with intractable vomiting
Patient declining oral medications
Need for more rapid onset or reliable absorption than oral can provide

Key Oral Medications in Palliative Care

💊

Morphine Sulfate (Immediate Release)

Ordine® · Sevre-Morphia® · Opioid analgesic

Adult dose 5–10 mg PO/SL every 4 hours (opioid-naïve); titrate every 24–48 h

Paediatric dose 0.2–0.4 mg/kg PO every 4 hours

Renal adjustment Reduce dose and extend interval if eGFR <30 mL/min; active metabolites (M6G, M3G) accumulate — prefer fentanyl or hydromorphone

PBS status ✔ PBS General Benefit

💊

Dexamethasone

Various · Corticosteroid

Adult dose 4–8 mg PO/IV/SC mane (anti-emetic, appetite, cerebral oedema); 16–24 mg for acute spinal cord compression

Paediatric dose 0.15–0.3 mg/kg/day PO (max 10 mg)

Renal adjustment No adjustment required

PBS status ✔ PBS General Benefit

💊

Ondansetron (Orodispersible)

Ondemet® · Zofran ODT® · 5-HT₃ antagonist

Adult dose 4–8 mg PO/SL every 8–12 hours

Paediatric dose 0.1–0.15 mg/kg PO every 8 hours (max 4 mg/dose)

Renal adjustment No adjustment required; caution with severe hepatic impairment (max 8 mg/day)

PBS status ✔ PBS General Benefit

Enteral Tubes

Enteral tube administration allows continued drug delivery through the gastrointestinal tract when oral swallowing is no longer possible or safe. In palliative care, enteral tubes are used selectively — the decision to place a tube must be guided by the patient's goals, prognosis, and the potential for reversibility of the swallowing impairment.

Types of Enteral Access

Tube Type	Insertion	Duration	Palliative Indication
Nasogastric (NG)	Bedside, nasally placed	Short-to-medium term (4–6 weeks)	Acute reversible dysphagia (e.g., post-radiotherapy mucositis, stroke recovery); rarely placed in last days of life
Nasoenteric (NJ)	Endoscopic or radiological; tip in jejunum	Short-to-medium term	Gastric outlet obstruction; gastroparesis; when gastric drug absorption is unreliable
PEG (Percutaneous Endoscopic Gastrostomy)	Endoscopic procedure (usually requires sedation)	Long term (months–years)	Considered only if prognosis >1–2 months and meaningful benefit; head/neck cancer with anticipated prolonged dysphagia
PEJ (Percutaneous Endoscopic Jejunostomy)	Endoscopic; tube enters jejunum	Long term	When gastric administration is contraindicated (e.g., gastroparesis, gastric surgery)

⚠️

Appropriate use in palliative care: PEG insertion in patients with advanced dementia or end-stage disease is generally not recommended. Multiple studies and guidelines (including NHMRC-endorsed consensus statements) indicate that hand-feeding and comfort care are preferred over tube feeding in advanced dementia. NG tubes may cause distress, and tube feeding has not been shown to improve survival or quality of life in this population.

Principles of Drug Administration via Enteral Tubes

Prefer liquid formulations where available — they require no preparation, are less likely to block the tube, and allow accurate dosing
If tablets must be crushed, check compatibility first — do NOT crush enteric-coated, sustained-release, or cytotoxic medications
Flush the tube with 15–30 mL of water before and after each medication to prevent blockage
Do not mix different medications together in the same syringe — drug interactions may cause precipitation
For jejunal tubes, only administer drugs that can be absorbed in the small bowel; proton pump inhibitors require gastric acid for absorption and may be ineffective via NJ/PEJ
Confirm tube position (aspirate pH <5.5 for gastric tubes; X-ray for initial NG placement) before administration

Drugs to Avoid via Enteral Tubes

Drug / Class	Reason	Alternative
Modified-release morphine (e.g., MS Contin®, Kapanol®)	Crushing destroys slow-release mechanism → dose dumping → respiratory depression	Use immediate-release morphine solution (Ordine®) via tube
Enteric-coated aspirin, mycophenolate	Coating designed to protect from gastric acid; destroying it may cause gastric irritation or altered absorption	Use plain formulations; IV mycophenolate (if available)
Sublingual buprenorphine (Temgesic®)	Designed for sublingual absorption; very low oral bioavailability via GI tract	Transdermal buprenorphine (Norspan®) or alternative opioid
Cytotoxic agents	Crushing creates hazardous powder; risk of exposure to carers	Consult oncology; alternative routes or formulations
Proton pump inhibitors (via NJ/PEJ)	Require gastric acid for activation; ineffective if bypassing stomach	IV pantoprazole or H₂-receptor antagonist (famotidine)

Ethical Considerations

In Australian palliative care, the decision to place an enteral tube should involve a goals-of-care discussion with the patient (if capable), family, and the multidisciplinary team. Tube placement for hydration or nutrition in the last weeks of life is generally considered non-beneficial and may prolong dying. Palliative Care Australia and the Australian & New Zealand Society of Palliative Medicine (ANZSPM) support the position that artificial nutrition is not obligatory in end-of-life care, and that comfort-focused oral care is more appropriate.

Transdermal Route

The transdermal route delivers medication across the skin into systemic circulation, providing a non-invasive, needle-free alternative that is particularly valuable in palliative care. It is ideal for patients who cannot swallow, have intractable nausea, or wish to avoid repeated injections. Transdermal delivery produces stable plasma drug concentrations, reducing peaks and troughs associated with intermittent dosing.

Available Transdermal Agents in Australian Palliative Care

🩹

Fentanyl Transdermal Patch

Durogesic® · Generic · Opioid μ-agonist

Available strengths 12, 25, 50, 75, 100 μg/h

Dosing Replace every 72 hours (some patients require every 48 h); convert from current opioid using equianalgesic tables

Onset 12–24 hours to therapeutic effect — must provide immediate-release opioid for breakthrough during initiation

Renal adjustment Preferred over morphine in renal impairment (no active metabolites); use with caution

PBS status 🔶 PBS Authority Required

🩹

Buprenorphine Transdermal Patch

Norspan® · Partial opioid agonist

Available strengths 5, 10, 20, 35, 52.5, 70 μg/h

Dosing Replace every 7 days (7-day patch); appropriate for mild-to-moderate pain

Onset 12–24 hours; similar onset delay to fentanyl patches

Renal adjustment No active metabolite accumulation; generally preferred in renal impairment

PBS status 🔶 PBS Authority Required

🩹

Hyoscine Hydrobromide Transdermal

Scopoderm® · Anticholinergic / Antisecretory

Available strengths 1.5 mg patch

Dosing One patch behind the ear every 72 hours; for nausea, secretions, or motion-related symptoms

Note Useful for managing terminal respiratory secretions when SC access is not available; also used prophylactically for nausea in transit

PBS status ✔ PBS General Benefit

Practical Considerations for Transdermal Patches

Skin Selection

Apply to flat, non-irradiated, hair-free skin (upper arm, chest wall, upper back). Avoid areas with oedema, scars, burns, or skin folds. Rotate application sites to prevent skin irritation.

Application

Clean skin with water only (no soap, alcohol, or moisturiser — these alter absorption). Press firmly for 30 seconds. Do not cut patches (unless specifically designed — e.g., some buprenorphine patches may be halved per manufacturer guidance).

Monitoring

Check patch adhesion regularly. Note that fever >38°C, external heat sources (hot water bottles, electric blankets), and high ambient temperatures can increase drug absorption and risk toxicity. Inform patients and carers of this risk.

Disposal

Fold used patches in half (adhesive sides together) and dispose of safely. Used patches retain significant residual drug — a major safety concern, especially for children and pets.

🚨

Transdermal fentanyl — NOT for opioid-naïve patients. Transdermal fentanyl patches (25 μg/h) are roughly equivalent to 60–90 mg oral morphine per 24 hours. Initiating fentanyl patches in opioid-naïve patients carries a high risk of fatal respiratory depression. The TGA and PBS restrictions require prior opioid tolerance documentation. Always use an immediate-release opioid for breakthrough pain during patch initiation.

Topical Agents (Non-Patch)

Several topical formulations are used adjunctively in palliative care for local symptom relief:

Lidocaine 5% medicated plasters (Versatis®) — for localised neuropathic pain; apply to affected area for 12 hours on / 12 hours off
Diclofenac gel (Voltaren Emulgel®) — for musculoskeletal pain; PBS General Benefit
Ketamine cream (compounded) — for neuropathic pain; not PBS-listed; use under specialist guidance
Glycopyrrolate (glycopyrronium) sublingual spray — for sialorrhoea; compounded formulation available through some Australian pharmacies

Subcutaneous Route

The subcutaneous (SC) route is the most commonly used parenteral route in Australian palliative care, both in hospital and community settings. SC administration avoids the complexity and infection risk of intravenous access and can be managed by community palliative care nurses, residential aged care staff, and in many cases by trained family carers.

Methods of SC Administration

Method	Description	Indication
Intermittent SC injection	Bolus injection via a 25–27G needle or butterfly needle into anterior thigh, abdomen, or upper arm	Single-dose breakthrough medications (e.g., morphine PRN); less frequent dosing requirements
Continuous SC infusion (syringe driver)	Programmable pump delivers a set volume over 24 hours via a subcutaneous butterfly needle	Continuous symptom control; multiple medications needed; unstable oral absorption; end-of-life care
Rapid SC bolus (SCI / SSCI)	Subcutaneous injection given as a rapid push when continuous infusion is impractical or for acute symptom crises	Acute breakthrough symptoms when syringe driver is not immediately available

Syringe Drivers in Australian Palliative Care

Syringe drivers (also called syringe pumps or continuous subcutaneous infusions) are an essential tool in Australian palliative medicine. Commonly used devices include:

Graseby™ MS16A / MS26 — widely used in Australian palliative care; lightweight, battery-operated
McKinley™ T34 — programmable; increasingly available in Australian hospitals and community services
CME Bodyguard™ — used in some settings; versatile

Syringe drivers typically run over a 24-hour cycle with total volumes of 1–60 mL/24 h depending on the device. The subcutaneous site is usually the anterior abdominal wall or the anterior thigh; the butterfly needle (e.g., BD Saf-T-Intima™ or similar) is replaced every 3–7 days or earlier if signs of site infection, inflammation, or leaking occur.

Common Syringe Driver Combinations

💡

The following are commonly used SC drug combinations in Australian palliative care practice. Doses are starting doses and should be titrated to effect. All doses are per 24 hours.

Symptom	Drug	Starting SC Dose (24 h)	Notes
Pain	Morphine	SC dose = ½ to ⅓ of previous 24-h oral dose (50% reduction for incomplete cross-tolerance)	Avoid in eGFR <30 — use fentanyl
Pain (renal impairment)	Fentanyl	Approximately ⅓ of the equianalgesic morphine SC dose	No active metabolites; preferred in renal failure
Nausea / Vomiting	Haloperidol	0.5–2 mg SC/24 h	First-line antiemetic via SC route; compatible in syringe driver
Nausea (dizziness-related)	Cyclizine	75–150 mg SC/24 h	May cause local site reactions; less commonly used SC than haloperidol
Secretions (death rattle)	Hyoscine butylbromide	40–80 mg SC/24 h (or 20 mg SC stat then 40–60 mg/24 h)	First-line; does NOT cross BBB (no sedation or confusion)
Secretions (alternatives)	Glycopyrronium (glycopyrrolate)	0.2–0.6 mg SC/24 h (or 0.2 mg SC stat)	Does not cross BBB; compatible with most syringe driver drugs
Agitation / Restlessness	Midazolam	10–30 mg SC/24 h (or 2.5–5 mg SC stat, repeatable)	First-line benzodiazepine for terminal agitation; compatible with morphine in syringe driver
Nausea (gastric stasis)	Metoclopramide	30–60 mg SC/24 h	Prokinetic + antiemetic; max 0.5 mg/kg/day to avoid extrapyramidal effects

🚨

Syringe driver compatibility: Not all drugs are physically or chemically compatible when mixed in the same syringe. Always consult an up-to-date compatibility chart (e.g., Palliative Care Therapeutic Guidelines or local palliative care service formulary). Common compatible combinations include morphine + midazolam + hyoscine butylbromide. Cyclizine and diazepam are generally NOT compatible with other drugs in syringe drivers — administer separately.

Conversion Ratios: Oral to Subcutaneous

Drug	Oral : SC Ratio	Example
Morphine	2:1 to 3:1 (oral:SC)	Oral morphine 60 mg/24 h → SC morphine 20–30 mg/24 h (reduce by 50% for incomplete cross-tolerance on first switch)
Hydromorphone	2:1 to 3:1 (oral:SC)	Oral hydromorphone 8 mg/24 h → SC hydromorphone 3–4 mg/24 h
Oxycodone	2:1 (oral:SC) approximated via morphine equivalency	Convert oxycodone to oral morphine equivalent first, then to SC morphine
Fentanyl	Patch to SC: variable — use conversion tables	Fentanyl 25 μg/h patch ≈ SC fentanyl 25 μg/h; a 72-h patch dose divided by 72 gives approximate hourly SC rate

⚠️

When converting between opioids: Always reduce the calculated equianalgesic dose by 25–50% to account for incomplete cross-tolerance. Titrate to effect over 24–48 hours. Ensure immediate-release breakthrough medication is available. Document conversions clearly in the medical record and communicate to all members of the care team, including community pharmacists.

SC Site Management

Rotate sites every 3–7 days, or sooner if redness, swelling, pain, or leakage develops
Preferred sites: anterior abdominal wall (below the costal margin, lateral to the umbilicus), anterior thigh, upper arm
Avoid oedematous areas, areas of lymphoedema, skin lesions, and sites of previous radiation
Use aseptic technique for insertion; secure the needle with a transparent dressing to allow site monitoring
Document site, date of insertion, and drugs running at each change

Patient and Carer Education

For patients receiving SC infusions at home, community palliative care services provide education to family carers regarding:

Recognising signs of site complications (redness, swelling, pain, leaking)
Understanding alarm signals on the syringe driver
When to contact the palliative care service or after-hours triage line
Safe storage of medications and disposal of sharps (sharps containers provided free in most Australian states and territories)

Special Populations

🫘 Renal Impairment

Morphine: Active metabolites (morphine-6-glucuronide, morphine-3-glucuronide) accumulate in renal failure causing prolonged sedation, myoclonus, and respiratory depression. Reduce dose by 50–75% or preferably avoid — use fentanyl or hydromorphone instead.

Fentanyl: Preferred opioid in moderate-to-severe renal impairment (eGFR <30). No active metabolites. Dose reduction still recommended for safety.

Hydromorphone: Preferred second-line alternative; less metabolite accumulation than morphine but some caution still required.

Midazolam: Active metabolite (α-hydroxymidazolam) may accumulate — reduce dose and monitor closely for excessive sedation.

Route considerations: SC route remains appropriate; avoid IM in cachectic patients with poor muscle mass. Transdermal fentanyl preferred over oral morphine.

🫁 Hepatic Impairment

General principle: Reduced hepatic metabolism prolongs drug half-lives. Start low, go slow. Reduce doses of hepatically cleared drugs (morphine, fentanyl, haloperidol, midazolam, most antiemetics).

Morphine: Oral bioavailability increases (reduced first-pass effect); paradoxically, oral dose may need greater reduction than parenteral dose.

Paracetamol: Maximum 2 g/day (not 4 g/day) in chronic liver disease; SC route is available if oral not tolerated.

Transdermal patches: Use with caution — hepatic impairment affects systemic drug clearance regardless of route of absorption.

👶 Paediatric Palliative Care

Weight-based dosing: All medication doses must be calculated per kg body weight. Use paediatric formulations where available (e.g., morphine solution 2 mg/mL for accurate small-volume dosing).

Transdermal patches: Fentanyl patches may be used in children >2 years who are opioid-tolerant, but limited evidence and PBS restrictions apply. Buprenorphine patches not routinely recommended in paediatrics.

SC infusions: Syringe drivers are used in paediatric palliative care; lower flow rates and smaller volumes required. Ensure paediatric palliative care expertise is involved.

Taste and formulation: Children are less able to tolerate bitter-tasting oral liquids; flavoured formulations and orodispersible wafers are preferred when available.

Carer support: Parents administering SC medications at home require comprehensive training and 24-hour support from the paediatric palliative care team.

🧓 Elderly Patients

Polypharmacy: Elderly palliative care patients are often on multiple medications. Regular review and deprescribing is essential to reduce pill burden and drug interactions.

Swallowing difficulties: Dysphagia is common in the elderly. Orodispersible formulations, liquids, and transdermal patches should be considered early.

Reduced renal function: eGFR declines with age; dose adjust renally cleared medications. Always calculate eGFR rather than relying on serum creatinine alone.

Falls risk: Opioids, benzodiazepines, and anticholinergics increase falls risk. Balance symptom control with safety; monitor closely.

Residential aged care: Medication administration in RACFs requires coordination with facility pharmacists; syringe drivers may require nurse education and support from the visiting palliative care team.

🤰 Pregnancy

Rare but important: Palliative care in pregnancy is uncommon but may arise with advanced malignancy diagnosed during pregnancy. Multidisciplinary input from obstetrics, neonatology, and palliative medicine is essential.

Opioids: Morphine and fentanyl are Category C in pregnancy. Use the minimum effective dose; avoid prolonged use near term (risk of neonatal respiratory depression and withdrawal).

Route selection: SC and transdermal routes are appropriate. Avoid unnecessary IV access. Oral route preferred if tolerated.

🛡️ Immunocompromised

Infection risk: SC butterfly sites and enteral tubes carry infection risk. Use strict aseptic technique. Monitor sites more frequently in neutropenic patients.

Thrombocytopenia: In patients with significant thrombocytopenia (platelets <20 × 10⁹/L), SC injections may cause haematoma. Apply pressure and consider platelet transfusion if clinically indicated.

Corticosteroids: Dexamethasone (oral or SC) is widely used in palliative care but may exacerbate immunosuppression. Weigh benefits against risks; lowest effective dose.

Aboriginal and Torres Strait Islander Health

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Australians experience a disproportionate burden of advanced and life-limiting illness, yet access to culturally safe palliative care remains inequitable. The AIHW reports that Indigenous Australians are less likely to receive specialist palliative care and more likely to die in hospital rather than at home or on country. Effective drug route selection and management must account for the unique circumstances faced by Indigenous patients, particularly those in remote and very remote communities.

Remote Pharmacy Access

Remote communities may lack a resident pharmacist or have limited stock of specialist palliative care medications (e.g., fentanyl patches, sublingual fentanyl). Ensure medications are sourced in advance through remote area health services, Royal Flying Doctor Service (RFDS), or Remote Area Aboriginal Health Services. The Remote Area Aboriginal Health Services program (RAAHS) can assist with timely medication supply.

Syringe Driver Availability

Syringe drivers may not be readily available in all remote clinics. Palliative care services should ensure equipment is pre-positioned and staff are trained. The RFDS and state-based palliative care outreach teams can provide support, equipment, and remote clinical guidance.

Cold Chain for Transdermal Patches

Fentanyl and buprenorphine patches do not require refrigeration but must be stored below 25°C. In tropical and remote communities where ambient temperatures exceed this, air-conditioned storage is essential. Heat exposure (including on the patient's skin in extreme heat) may increase drug absorption unpredictably.

Language and Health Literacy

English may not be the first language for many Indigenous patients. Medication instructions, including patch application, site care, and syringe driver alarm responses, should be provided in plain language and, where possible, in the patient's preferred language using Aboriginal Interpreter Services (AIS) or Torres Strait Islander interpreter services. Visual and pictorial resources are valuable.

Cultural Preferences for End-of-Life Care

Many Aboriginal and Torres Strait Islander people have strong cultural preferences for dying on country. This may necessitate community-based palliative care with SC infusions managed by visiting nurses or trained family members. Early advance care planning discussions that respect cultural values are essential. Involvement of Aboriginal Health Workers/Practitioners (AHW/Ps) and local Elders supports culturally safe care delivery.

Aboriginal Health Workers and Practitioners

AHW/Ps play a critical role in bridging clinical and cultural care. They can assist with medication education, administration support, family communication, and liaison between the patient and the palliative care team. Their involvement should be actively sought and funded through Aboriginal Community Controlled Health Organisations (ACCHOs).

Stigma and Misconceptions

Opioid stigma may be present. Patients and families may associate morphine with "giving up" or fear addiction. Sensitive, culturally appropriate education about symptom management and the role of opioids in comfort care should be provided. Using words like "comfort medicine" rather than "morphine" or "narcotics" may improve acceptance, depending on local community preferences.

💚

Cultural safety principle: Involve Aboriginal and Torres Strait Islander health professionals in all aspects of palliative medication management. Recognise that decisions about medication routes, end-of-life care, and place of death are deeply personal and culturally informed. Respect family and community decision-making processes, which may differ from the Western individual-autonomy model. Refer to the Australian Indigenous Doctors' Association (AIDA) position statement on end-of-life care for further guidance.

📚 References

1. Palliative Care Australia. National Palliative Care Standards. 5th ed. Canberra: Palliative Care Australia; 2018.
2. Australian Institute of Health and Welfare (AIHW). Palliative care services in Australia. Cat. no. HWU 214. Canberra: AIHW; 2023.
3. Royal Australian College of General Practitioners (RACGP). Care of patients with advanced chronic conditions: A guide for general practice. Melbourne: RACGP; 2020.
4. Currow DC, Agar MR, To THM, et al. Prescribing in palliative care as death approaches. J Pain Symptom Manage. 2020;59(1):143–152.
5. Australian & New Zealand Society of Palliative Medicine (ANZSPM). Position statement on artificial nutrition and hydration in palliative care. Sydney: ANZSPM; 2019.
6. Fallon M, Giusti R, Aielli F, et al. Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2018;29(Suppl 4):iv166–iv191.
7. National Health and Medical Research Council (NHMRC). Decision-making for the provision of futile or non-beneficial treatment to adults: A guide for clinicians. Canberra: NHMRC; 2020.
8. Hägerbäumer E, Müller-Mundt G, Engeser P, et al. Drugs and dosage forms for use in palliative care via syringe drivers: A systematic review. J Pain Symptom Manage. 2021;62(2):375–388.
9. Australian Medicines Handbook (AMH). Australian Medicines Handbook. Adelaide: AMH Pty Ltd; 2024.
10. Department of Health and Aged Care. Schedule of Pharmaceutical Benefits. Canberra: Commonwealth of Australia; 2024. Available at: pbs.gov.au.
11. Palliative Care Therapeutic Guidelines Writing Group. Palliative Care: Therapeutic Guidelines. Melbourne: Therapeutic Guidelines Limited; 2023.
12. Davis MP, Bruera E. Interventional pain management in palliative care. In: Walsh D, Caraceni AT, Fainsinger R, et al., eds. Palliative Medicine. Philadelphia: Saunders Elsevier; 2009:363–372.
13. Australian Indigenous Doctors' Association (AIDA). Position statement on end-of-life care for Aboriginal and Torres Strait Islander Australians. Canberra: AIDA; 2020.
14. Shahid S, Finn L, Thompson SC. Barriers to participation of Aboriginal people in cancer care: communication in the hospital setting. Med J Aust. 2009;190(10):574–579.
15. Royal Australian College of Physicians (RACP). Chronic kidney disease management in primary care. 4th ed. Sydney: RACP; 2020.

for PBS scripts. Utilise ACCHS pharmacies and Remote Area Aboriginal Health Worker programs for medication supply in remote areas. Avoid initiating benzodiazepines; support holistic pain management including community-based exercise programs.

Preventive health

Promote bone health: encourage vitamin D supplementation (1000 IU daily in deficient individuals), smoking cessation support, reduction of alcohol intake, and weight-bearing exercise. MBS Item 715 health checks provide a structured opportunity to assess bone health, screen for osteoporosis risk factors, and discuss musculoskeletal health in a culturally safe context.

Quick Reference: Differential Diagnosis at a Glance

Costovertebral dysfunction

Paracetamol ± NSAID; manual therapy

2–6 weeks

Provocable on palpation; no red flags

Thoracic compression fracture

Paracetamol; ± calcitonin; DXA + osteoporosis Rx

6–12 weeks healing

Elderly; osteoporosis; acute onset

ACS (posterior MI)

Aspirin 300 mg, GTN, heparin; urgent PCI

Time-critical

ECG, troponin; CV risk factors

Aortic dissection

IV labetalol; urgent CT aortogram; surgery (Type A)

Time-critical

Tearing pain; BP differential >20 mmHg

Vertebral osteomyelitis

IV antibiotics (vancomycin + ceftriaxone initially); ID consult

6 weeks IV antibiotics

Fever, elevated CRP, IV drug use

Biliary colic / cholecystitis

Paracetamol ± morphine; lap cholecystectomy

Surgical within 72 h (cholecystitis)

RUQ/infrascapular; post-prandial; RUQ US

📚 References

1. Briggs AM, Smith AJ, Straker LM, Bragge P. Thoracic spine pain in the general population: prevalence, incidence and associated factors in children, adolescents and adults. A systematic review. BMC Musculoskelet Disord. 2009;10:77.
2. National Health and Medical Research Council (NHMRC). Evidence-based management of acute musculoskeletal pain. Canberra: NHMRC; 2003 (updated 2020).
3. Australian Institute of Health and Welfare (AIHW). Aboriginal and Torres Strait Islander Health Performance Framework: Summary report 2023. Canberra: AIHW; 2023.
4. Deyo RA, Rainville J, Kent DL. What can the history and physical examination tell us about low back pain? JAMA. 1992;268(6):760–765.
5. Stochkendahl MJ, Kjaer P, Hartvigsen J, et al. National Clinical Guidelines for non-surgical treatment of patients with recent onset low back pain or lumbar radiculopathy. Europ Spine J. 2018;27(1):60–75.
6. Erwin WM, Jackson PC, Homonko DA. Innervation of the human costovertebral joint: implications for clinical back pain syndromes. J Manipulative Physiol Ther. 2000;23(6):395–403.
7. Royal Australian College of General Practitioners (RACGP). Guidelines for preventive activities in general practice. 9th edn. Melbourne: RACGP; 2018 (updated 2023).
8. Hirsch JA, Singh V, Falco FJE, et al. Thoracic facet joint interventions. Pain Physician. 2016;19(4):E581–E593.
9. Erwin WM, Jackson PC. The costovertebral joint: anatomy, biomechanics, and clinical significance in thoracic back pain syndromes. J Can Chiropr Assoc. 2003;47(2):112–120.
10. Strayer RJ, Gunnerson JM, Brown LH, et al. Aortic dissection: clinical features, diagnosis, and management. Aust Crit Care. 2019;32(2):144–153.
11. Ombregt L. A system of orthopaedic medicine. 3rd edn. Edinburgh: Churchill Livingstone Elsevier; 2013. Chapter 18: Thoracic spine.
12. Lin CC, Chen KH, Li DM, et al. Characteristics and outcomes of patients presenting with thoracic back pain to the emergency department. Emerg Med Australas. 2020;32(5):805–811.

for PBS-listed medicines at participating pharmacies.

Cultural safety

Engagement with Aboriginal Community Controlled Health Organisations (ACCHOs) is essential. Cultural safety training for non-Indigenous clinicians, use of Aboriginal Health Workers and Liaison Officers, and incorporation of traditional healing practices alongside Western medicine improve treatment adherence and outcomes. Avoidance of eye contact, respect for gender-sensitive examination practices, and understanding of sorry business protocols are critical elements of culturally safe care.

Medication adherence

Complex DMARD regimens with frequent monitoring requirements present adherence challenges. Long-acting depot injections (e.g., methotrexate SC) may improve adherence compared to oral regimens. Community pharmacy partnerships through the Indigenous Pharmacy Programmes improve medication management.

Specific conditions

Rheumatic heart disease (RHD) requires secondary prophylaxis with benzathine penicillin G (BPG) 1.2 MU IM every 3–4 weeks for a minimum of 10 years or until age 21 (whichever is longer). RHD registers (e.g., NT RHD Register) facilitate recall and follow-up. The Australian RHD Endgame Strategy targets elimination by 2031.

Referral pathways

Referral through ACCHOs and Aboriginal Hospital Liaison Officers (AHLOs) improves engagement. The Specialist Outreach Assistance Programme provides funded specialist visits to remote communities. NT, WA, and QLD have specific rheumatology outreach programmes targeting Indigenous communities.

📚 References

1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939.
3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583–1599.
5. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487–1498.
10. Pisetsky DS. Antinuclear antibody testing — misunderstood or misused? Clin Immunol. 2023;255:109717.
11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155–158.
13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).

for PBS-listed medicines at participating pharmacies.

Cultural safety

Medication adherence

Specific conditions

Referral pathways

📚 References

1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939.
3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583–1599.
5. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487–1498.
10. Pisetsky DS. Antinuclear antibody testing — misunderstood or misused? Clin Immunol. 2023;255:109717.
11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155–158.
13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).